基准医疗
Location: China, Guangdong Province, Guangzhou City
Employees: 51-200
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | 6 Dimensio... | 6dimension... |
| - | OrbiMed | orbimed.co... |
| - | Marathon V... | marathonvp... |
| - | Northern L... | nlvc.com |
Mentions in press and media 6
| Date | Title | Description |
| 23.11.2022 | AnchorDx Enrolls the First Patient For Its UriFind® Bladder Cancer Assay Clinical Trial in the U.S. | GUANGZHOU, China, Nov. 23, 2022 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer early detection solutions, announced the first patient enrollment for the UriFind® bladder cancer assay clinical trial in the U.S., an over 1,000-... |
| 15.06.2022 | AnchorDx's Non-invasive Lung Cancer Early Diagnosis Product, PulmoSeek, Completes EU CE Marking Requirements | The company obtained a European Access Permit for in-vitro diagnostics devices (IVDD) authorized by the Netherlands CIBG of Ministry of Health, Welfare and Sport. GUANGZHOU, China, June 15, 2022 /PRNewswire/ -- PulmoSeekTM Lung Cancer Early... |
| 13.09.2021 | AnchorDx Develops New Liquid Biopsy Diagnostic Model for Early Detection of Breast Cancer | GUANGZHOU, China, Sept. 13, 2021 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screening and early detection solutions, together with renowned experts from a top-tier hospital in China, jointly published an article entitled ... |
| 21.07.2021 | AnchorDx's Non-invasive Bladder Cancer Early Detection Test, UriFind, Earns "Breakthrough Device Designation" from FDA | GUANGZHOU, China, July 21, 2021 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screening and early detection solutions, on July 13, 2021, was awarded a Breakthrough Device Designation ("BTD")[1] by the US Food and D... |
| 21.06.2021 | 2021 ASCO - AnchorDx Unveils Robust Validation Result of Multi-cancer Screening Technology AURORA | GUANGZHOU, China, June 21, 2021 /PRNewswire/ -- At this year's American Society of Clinical Oncology (ASCO) Annual Meeting 2021 (June 4-8), AnchorDx, a world-leading developer of cancer screening and early detection solutions, unveiled furt... |
| 24.02.2021 | AnchorDx Closes USD 40M Series C Financing | AnchorDx Medical Co., Ltd., a Guangzhou, China-based developer of DNA methylation NGS products, closed a USD40m Series C financing. The round was jointly led by OrbiMed and WuXi Huiying Investment. The company plans to use the new funds to ... |